Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

IMM-BCP-01 targets three non-overlapping regions on the Spike protein to provide broad coverage across CDC current and former variants of concern

– IMM-BCP-01 elicits multi-modal activity in pre-clinical testing including ACE2 and non-ACE2 dependent neutralization, as well as natural viral clearance mechanisms

See more here


Immunome Reports Third Quarter 2021 Financial Results

– IMM-BCP-01 Progressing Towards IND Filing –

See more here


Renovacor Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Debuted as a public company and strengthened liquidity position with $95.1 million in gross proceeds from the business combination with Chardan Healthcare Acquisition 2 Corp and concurrent PIPE financing

Released topline preclinical data demonstrating feasibility of REN-001 to transduce a large animal heart via local infusion at low vector doses

Strengthened company leadership with key appointments including Matthew Killeen, Ph.D., as CSO, and Elizabeth White, Ph.D., as CBO and SVP of Operations

See more here


Data from ImmunoGenesis’ Lead Programs Presented in Six Posters at Society for Immunotherapy of Cancer (SITC) Conference

See more here


Relmada Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results 

See more here


Wellsheet Collaborates with Horizon to Provide Clinicians with a Single View of Key Data and Insights within their EHR Workflow 

New Jersey Health Providers Can Access a Near Real-Time Comprehensive View of Patients’ Medical History

See more here


Venatorx Pharmaceuticals Announces Collaboration with Roche to Develop New Class of Antibiotics targeting WHO Critical Priority Pathogen 

Development of novel antibiotics to circumvent antimicrobial resistance and address increasing threat of superbugs

See more here


Phrase Health Announces $3M Investment from Health IT Leaders: LionBird, Vizient, Inc., and BioAdvance 

The new investment will enhance growth initiatives, accelerate development, and support additional research to enhance platform capabilities.

See more here


Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

See more here